Trials / Completed
CompletedNCT00038532
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first protease inhibitor based HAART.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amprenavir/ritonavir | |
| DRUG | Saquinavir/ritonavir | |
| DRUG | Efavirenz |
Timeline
- Start date
- 2001-04-01
- First posted
- 2002-06-03
- Last updated
- 2008-04-01
Locations
54 sites across 11 countries: United States, Argentina, Brazil, Canada, France, Germany, Italy, Poland, Puerto Rico, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00038532. Inclusion in this directory is not an endorsement.